Gene Network Sciences
This article was originally published in Start Up
Executive Summary
Researchers at Gene Network Sciences (GNS) are on a mission to solve the drug industry's agonizing R&D productivity problem. Their answer: predictive computer simulations designed to reduce drug discovery time by one-third and cut R&D costs in half. As they evolve, these simulations will show how human cancer and bacterial cells behave, providing insight into which protein targets or combinations thereof will yield the strongest therapeutic impact.
You may also be interested in...
Deals Of The Week: United Therapeutics/Ascendis, Baxter/Onconova, Bionomics/Eclipse
The growing importance of emerging markets was a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
Systems Biology: The Post Proteomics Era Begins?
Several emerging companies are building platforms around the concept of systems biology, which is premised on the idea that drug and diagnostic discovery require studying the ways in which the various elements of biological systems-including, but not limited to, genes and proteins-integrate and interact within an organism or function. This ambitious undertaking requires an arsenal of high-throughput technology and expertise drawn from a myriad of disciplines including chemistry, bioanalysis, molecular and cell biology, medicine, and informatics. The immediate challenge facing aspiring systems biology companies is to sustain themselves by creating sufficient value from their expansive technologies during the years it will take to come up with a novel diagnostic or therapeutic. Along with traditional discovery deals, as well as deals to resurrect partners' projects which have failed for lack of understanding about their proper use, several players are proposing interim steps to create product businesses, like using their technologies to find undervalued in-licensing candidates.
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.